Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 714-716, Vol. 7, No. 4
University of Colorado Health Sciences
Center, Denver, Colorado1; University of
Minnesota, Minneapolis, Minnesota2; St.
Luke's-Roosevelt Hospital Center, New York, New
York3; Massachusetts General Hospital, Harvard
School of Public Health, Boston,
Massachusetts4; and Frontier
Science & Technology Research Foundation5
and Adult AIDS Clinical Trials Group Operations
Center,6 Washington, D.C.
Received 18 January 2000/Returned for modification 21 March
2000/Accepted 11 May 2000
Factors that influence viability and function of cryopreserved
peripheral blood mononuclear cells (PBMC) were identified on 54 samples
from 27 AIDS Clinical Trial Units. PBMC viability ranged from 1 to 96%
with a median of 70%, was higher in laboratories with experienced
staff, and was not significantly associated with CD4 cell number.
Function of cryopreserved PBMC, measured by lymphocyte proliferation,
was associated with viability. Preparations with viability greater than
or equal to 70% had consistent proliferative responses and were
suitable for functional analyses.
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Viability and Functional Activity of Cryopreserved
Mononuclear Cells
*
Corresponding author. Mailing address: University of
Colorado Health Sciences Center, Campus box C227, 4200 East Ninth Ave., Denver, CO 80262. Phone: (303) 315-4624. Fax: (303) 315-6955. E-mail:
adriana.weinberg{at}uchsc.edu.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |